ASX Share rice
Fri 07 Aug 2020 - 02:56:am (Sydney)

CUV Share Price

CLINUVEL PHARMACEUTICALS LIMITEDCUVPharmaceuticals, Biotechnology & Life Sciences

CUV Company Information

Name:

Clinuvel Pharmaceuticals Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Biotechnology

GIC Sub Industry:

Biotechnology

Address:

535 Bourke Street Melbourne VIC Australia 3000

Phone:

61 3 9660 4900

CEO, MD & Director:

Dr. Philippe Jacques Wolgen M.B.A., MBA, M.D.

CFO & Company Sec.:

Mr. Darren M. Keamy

Acting Chief Scientific Officer:

Dr. Dennis J. Wright BPharm, M.Sc., Ph.D.

Head of Investor Relations:

Mr. Malcolm Bull

Gen. Mang. of Europe:

Lachlan Hay

Company Overview:

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of severe genetic and skin disorders in Europe, the United States, and Singapore. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria. The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and VLRX001, an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited for launching SCENESSE under a named patient program for the treatment of patients with erythropoietic protoporphyria in the People's Republic of China. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.

CUV Share Price Information

Shares Issued:

49.41M

Market Capitalisation:

$1.10B

Dividend per Share:

$0.03

Ex Dividend Date:

2019-09-04

Dividend Yield:

0.13%

Revenue (TTM):

$32.04M

Revenue Per Share (TTM):

$0.66

Earnings per Share:

$0.303

Profit Margin:

0.4719

Operating Margin (TTM):

$0.46

Return On Assets (TTM):

$0.17

Return On Equity (TTM):

$0.30

Quarterly Revenue Growth (YOY):

0.11

Gross Profit(TTM):

$30.60M

Diluted Earnings Per Share (TTM):

$0.303

QuarterlyEarnings Growth(YOY):

-0.744

CUV CashFlow Statement

CashFlow Date:

2019-06-30

Investments:

$-257,616

Change To Liabilities:

$1.49M

Total Cashflow From Investing Activities:

$-257,616

Net Borrowings:

$-73,506

Net Income:

$18.13M

Total Cash From Operating Activities:

$18.46M

Depreciation:

$214.16K

Dividends Paid:

$-957,160

Change To Inventory:

$-1,494,799

Change To Account Receivables:

$0.93M

Capital Expenditures:

$257.62K

CUV Income Statement

Income Date:

2019-06-30

Income Before Tax:

$18.11M

Net Income:

$18.13M

Gross Profit:

$24.18M

Operating Income:

$16.69M

Interest Expense:

$21.11K

Income Tax Expense:

$-19,333

Total Revenue:

$31.05M

Total Operating Expenses:

$7.49M

Cost Of Revenue:

$6.87M

CUV Balance Sheet

Balance Sheet Date:

2019-06-30

Total Liabilities:

$5.17M

Total Stockholder Equity:

$57.18M

Other Current Liabilities:

$2.13M

Total Assets:

$62.35M

Common Stock:

$151.31M

Retained Earnings:

$-95,486,738

Other Liabilities:

$34.21K

Good Will:

$185.03K

Other Assets:

$301.11K

Cash:

$54.27M

Total Current Liabilities:

$4.96M

Property - Plant & Equipment:

$706.66K

Net Tangible Assets:

$56.99M

Total Current Assets:

$61.15M

Net Receivables:

$3.76M

Short-Term Investments:

$1.19M

Inventory:

$2.14M

Accounts Payable:

$1.50M

Non Currrent Assets (Other):

$1.19M

Short-Term Investments:

$1.19

Non Current Liabilities Total:

$205.48K

CUV Share Price History

CUV News

14 Jul, 2020
A look at the shareholders of Clinuvel Pharmaceuticals Limited (ASX:CUV) can tell us which group is most powerful...
13 Jul, 2020
MELBOURNE, Australia and SINGAPORE, July 13, 2020 -- CLINUVEL PHARMACEUTICALS today revealed PRÉNUMBRA®, the Company’s second afamelanotide product in development. PRÉNUMBRA®.
03 May, 2020
It hasn't been the best quarter for Clinuvel Pharmaceuticals Limited (ASX:CUV) shareholders, since the share price has...
23 Apr, 2020
MELBOURNE, Australia and HANGZHOU, China, April 23, 2020 -- Australian-based company CLINUVEL is launching SCENESSE® (afamelanotide 16mg) in the People’s Republic of China for.
16 Apr, 2020
Americans living with a rare genetic disorder that forces them to choose between self-isolation in the dark, or burning reactions from exposure to light, are welcoming an approved treatment for the first time ever. Australian-based company CLINUVEL has launched SCENESSE® (afamelanotide)1 in the USA for the rare disease erythropoietic protoporphyria (EPP), with the first US insurance companies initiating reimbursement for treatment under Prior Authorization or as included in their listed formulary. Just one in 140,000 Americans is thought to live with EPP, an inherited disorder which causes debilitating invisible reactions whenever patients expose themselves to visible light, particularly sunlight.
19 Mar, 2020
Unfortunately for some shareholders, the Clinuvel Pharmaceuticals (ASX:CUV) share price has dived 44% in the last...
28 Feb, 2020
Unfortunately for some shareholders, the Clinuvel Pharmaceuticals (ASX:CUV) share price has dived 37% in the last...
04 Feb, 2020
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of...
06 Jan, 2020
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
06 Nov, 2019
Philippe Wolgen has been the CEO of Clinuvel Pharmaceuticals Limited (ASX:CUV) since 2005. This report will, first...
09 Oct, 2019
Australian drugmaker Clinuvel Pharmaceuticals Ltd said on Wednesday the pricing of its recently approved treatment for a rare genetic disorder in the United States will not top its price in Europe. The drug, Scenesse, was approved by the U.S. Food and Drug Administration on Tuesday to treat erythropoietic protoporphyria (EPP), a painful disorder that causes the skin to itch, burn, and scar in some rare cases, when exposed to sunlight and some types of artificial light. Scenesse is available in Europe since 2014, where its price ranges between 70,000 euros ($76,811.00) and 100,000 euros ($109,730.00) per patient per year.
08 Oct, 2019
The US Food and Drug Administration (FDA) has approved a new drug as the first ever treatment for a rare genetic metabolic disorder which causes absolute intolerance to light. SCENESSE® (afamelanotide 16mg), the first drug developed by Australian biopharmaceutical company CLINUVEL, has been approved to “increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP)”.
The U.S. Food and Drug Administration approved Australian drugmaker Clinuvel Pharmaceuticals Ltd's treatment for a rare inherited disorder that causes skin damage from exposure to light, sending its shares to a record high on Wednesday. The treatment, Scenesse, is an under-the-skin implant that treats erythropoietic protoporphyria (EPP), a painful disorder that causes the skin to itch, burn, and scar in some rare cases, when exposed to sunlight and some types of artificial light. "With the approved New Drug Application, Scenesse is the first global systemic photoprotective drug for the treatment of patients with EPP," Clinuvel said in a statement to the Australian stock exchange.
07 Oct, 2019
It hasn't been the best quarter for Clinuvel Pharmaceuticals Limited (ASX:CUV) shareholders, since the share price has...
12 Sep, 2019
Clinuvel Pharmaceuticals Limited's (ASX:CUV) most recent earnings announcement in August 2019 confirmed that the...
19 Aug, 2019
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...

CUV Dividend Payments

EX-Date Dividend Amount
2018-09-21$0.0200
2019-09-04$0.0250